Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma

Purpose Paclitaxel plus ramucirumab is a standard second-line regimen for patients with advanced gastric adenocarcinoma, but clinical benefit remains modest. One potential resistance mechanism to VEGFR2 inhibition is activation of the PDGF/PDGFR pathway, which can be blocked by the selective inhibit...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology Vol. 89; no. 2; pp. 255 - 265
Main Authors: Moy, Ryan H., Greally, Megan, Chou, Joanne F., Li, Jia, Desai, Avni M., Chalasani, Sree B., Won, Elizabeth, Kelsen, David P., Ilson, David H., Janjigian, Yelena Y., Capanu, Marinela, Ku, Geoffrey Y.
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2022
Springer Nature B.V
Subjects:
ISSN:0344-5704, 1432-0843, 1432-0843
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first